Inducing mitochondrial dysfunction has been recently demonstrated to be an alternative therapeutic strategy for cancer treatment. Doxycycline is an antibiotic that has been shown to have anti-cancer activities in various cancers by way of targeting mitochondria. In this work, we examined whether doxycycline can be repurposed for glioblastoma treatment.
Background
Glioblastoma is the most malignant brain tumor in adults with a one year survival rate less than 40% [1] . Standard treatments for glioblastoma are surgery, followed by a combination of radiation and chemotherapy with temozolomide. However, its clinical management is still challenging and its resistance to therapy is attributed to massive vascularization and molecular heterogeneity [2, 3] . Studies on transcript profiling and genomic aberrations have shown that glioblastoma is intra-and inter-tumor heterogeneous [4, 5] . Therefore, alternative therapeutic strategies for glioblastoma treatment could be to identify compounds/drugs that target what is common between different subclasses of glioblastoma, such as tumor metabolism.
Doxycycline is a FDA-approved antibiotic used in the treatment of a number of types of bacterial and protozoan infections. It kills bacteria by inhibiting protein synthesis via binding to bacterial ribosomes [6] . However, its anti-cancer activities have been recently demonstrated in various studies. Doxycycline has been shown to suppress the growth of cervical cancer, human breast cancer metastasis, and tumor-sphere formation in a panel of cancer cell lines, including lung cancer and prostate cancer cell lines [7] [8] [9] . Besides tumor cells, doxycycline also targets cancer stem cells [10] . The mechanisms of doxycycline's anti-cancer activities might be due to its ability in altering energy metabolism [8, 11] . Nevertheless, the effects of doxycycline in glioblastoma are unknown.
In our study, we investigated the effects of doxycycline alone and in combination with temozolomide on glioblastoma using in vitro culture cell system and an in vivo xenograft mouse model. We showed that doxycycline effectively targets glioblastoma cells and enhances the inhibitory effects of temozolomide. We further demonstrated that the inhibitory effects of doxycycline in glioblastoma were attributed to its induction of mitochondrial dysfunction and oxidative stress.
Material and Methods

Human cell lines and drugs
Human glioblastoma cell lines A172 and U87 were purchased from Sigma. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Life technologies, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, UK) and 2 mM L-glutamine (Invitrogen) according to manufacturer's instructions. Doxycycline, N-Acetyl-L-cysteine (NAC) and temozolomide (Sigma, USA) were dissolved in water and DMSO, respectively.
Analysis of cell proliferation and apoptosis
Cells were treated with doxycycline alone or in combination for 72 hours. Cell proliferation was determined by CellTiter 96R AQueous One Solution Cell Proliferation assay kit (Promega, USA) according to manufacturer's instructions. Cell apoptosis was determined by labeling apoptotic cells with Annexin V-FITC and 7-AAD (BD Biosciences, USA). The percentage of stained cells was then analyzed using flow cytometry and CXP analysis software (Beckman Coulter, USA).
Western blot analyses
Cells were treated with drug for 24 hours. Cells were then lysed by RIPA buffer (Life Technologies Inc, USA) supplemented with protease inhibitor cocktail (Roche, USA). Total protein concentration was measured using the bicinchoninic acid protein assay kit (Thermo Scientific, USA). Equal amount of total proteins were resolved using denaturing Denaturing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and were then processed for WB analyses using antibodies against PCNA, caspase 3 and b-actin (Santa Cruz Inc., USA).
Metabolic assays
Cells were treated with drugs for 24 hours prior to performing metabolic assays. Oxygen consumption rate (OCR) was measured using a Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience, USA) according to Seahorse Bioscience protocols [12] . Cells were first equilibrated to the unbuffered medium in a CO 2 -free incubator and then transferred to the XF24 analyzer. Basal OCR was measured at basal condition and maximal OCR was measured after injection of 0.5 μM oligomycin, 0.5 μM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) and 0.25 μM antimycin A. Mitochondrial potential was measured by labeling cells with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl benzimidazolylcarbocyanine iodide (JC-1, Invitrogen) prior to being read on a flow cytometer (Beckman Coulter, USA). ATP levels were measured by using ATPlite Luminiescent Assay kit (Perkin Elmer, USA). 
Measurement
Statistical analyses
For in vitro cell assays, the error bars indicated the value of standard deviation among three independent experiments. For in vivo mouse model work, the error bars indicated the value of standard deviation among 10 mice in each group. Unpaired Student's t-test was used in the statistical analysis for a comparison of categorical variables. A p value less than 0.05 was deemed as statistically significant.
Results
Doxycycline effectively targeted glioblastoma cells.
We first investigated whether doxycycline has effects on growth and survival of human glioblastoma using U87 and A172 cell lines. Both cell lines are derived from patients with glioblastoma and have been widely used as glioblastoma cell models [13] . The MTS proliferation results showed that doxycycline at 10 µM to 40 µM significantly inhibited proliferation of U87 and A172 cells in a dose-dependent manner ( Figure 1A ). Doxycycline also induced apoptosis in glioblastoma cells as assessed by quantifying the percentage of Annexin V and 7-AAD positive cells ( Figure 1B) . Notably, the effector concentration for half-maximal response (EC50) of doxycycline to A172 and U87 was similar at ~20 µM ( Figure 1A, 1B) , suggesting that doxycycline effectively targets glioblastoma regardless of their cellular origin. The inhibitory effects of doxycycline on growth and survival of glioblastoma cells were further confirmed by the decreased level of proliferating cell nuclear antigen (PCNA) and increased level of cleaved caspase 3 in A172 and U87 cells exposed to doxycycline ( Figure 1C ). Doxycycline induced apoptosis in normal primary neuronal cells to a significant lesser extent than in glioblastoma cells (Supplementary Figure 1) , suggesting that glioblastoma cells were more sensitive to normal neuronal cells than neuron cancer cells.
Doxycycline significantly induced mitochondrial dysfunctions and oxidative stress in glioblastoma cells
Doxycycline has been reported to target cancer cells via inhibiting mitochondrial biogenesis [8, 9] . Given the importance of mitochondrial metabolism in cancer cells, we investigated whether doxycycline affects mitochondrial functions in glioblastoma cells by measuring mitochondrial membrane potential, mitochondrial respiration, and ATP levels. We observed decreased mitochondrial membrane potential in glioblastoma cells treated with doxycycline ( Figure 2A ). Mitochondrial respiration was measured at both basal and maximal conditions using the Seahorse XF24 extracellular flux analyzer. Doxycycline decreased basal level of mitochondrial respiration as well as respiratory capacity in glioblastoma cells ( Figure 2B, 2C) . Consistently, ATP levels were decreased in doxycycline-treated U87 and A172 cells ( Figure 2D ). These results correlated well with each other, demonstrating that doxycycline disrupted mitochondrial functions in glioblastoma cells.
Mitochondrial dysfunction is one of the main sources of oxidative stress in normal and cancer cells [14] . In cell lines with mitochondrial dysfunctions in glioblastoma cells exposed to doxycycline, we also observed increased levels of mitochondrial superoxide (a precursor to many other forms of ROS) and intracellular ROS (Figure 2E, 2F) . These results clearly demonstrated that doxycycline induced energy crisis which leads to oxidative stress in glioblastoma cells.
Doxycycline caused oxidative damage to glioblastoma cells
We further investigated whether the oxidative stress induced by doxycycline caused any oxidative damage to glioblastoma cells. 8-hydroxy-2'-deoxyguanosine (8-OHdG, an oxidized DNA by product), protein carbonyls (a modification of proteins resulting from oxidative damage) and MDA (an end product of lipid peroxidation) were quantified. We found significantly elevated levels of 8-OHdG, protein carbonylation, and lipid peroxidation in A172 and U87 cells exposed to doxycycline (Figure 3 ), indicating that oxidative stress induced by doxycycline caused oxidative damage to glioblastoma cells.
Antioxidants reversed the effects of doxycycline in glioblastoma cells
To confirm that doxycycline acts on glioblastoma cells via oxidative damage in lung cancer cells, we investigated whether antioxidants NAC or vitamin C can rescue the effects of doxycycline in glioblastoma cells. NAC is a ROS scavenger that acts through inhibition of thiol redox-mediated ROS production [15] . We found that the effect of doxycycline in inducing oxidative stress was abolished by NAC or vitamin C in U87 and A172 cells ( Figure 4A and Supplementary Figure 2A) . Importantly, NAC or vitamin C significantly reversed the anti-proliferative and pro-apoptotic effects of doxycycline in U87 and A172 cells ( Figure 4B , 4C and Supplementary Figure 2B, 2C) , suggesting that oxidative stress was required for the action of doxycycline in glioblastoma cells.
Doxycycline sensitizes glioblastoma cells to chemotherapy in vitro and in vivo
To further explore the translational potential of doxycycline into clinics, we investigated the combinatory effects of doxycycline with standard chemotherapeutic drug and its in vivo efficacy. We found that the combination of doxycycline and temozolomide resulted in greater efficacy than doxycycline or temozolomide alone in inhibiting proliferation and inducing apoptosis in A172 and U87 cells ( Figure 5A , 5B). We next established a glioblastoma xenograft mouse model by injecting A172 cells into the flank of SCID mice. After the development of palpable tumors, mice were treated with either vehicle, doxycycline, temozolomide, or a combination for 30 days. All mice tolerated the treatment well. Doxycycline at 100 mg/kg and temozolomide at 20 mg/kg alone slightly inhibited tumor growth ( Figure 5C ). In contrast, the combination of doxycycline and temozolomide significantly inhibited tumor growth compared to single drug alone throughout the whole treatment duration ( Figure 5C ).
Discussion
Energy metabolism presents a potential therapeutic target for cancer given that tumors are fast growing and highly demanding of energy in comparison to surrounding normal tissues [16] [17] [18] . Interestingly, contrary to the classical Warburg view, recent studies have suggested that tumor cells in nutritionally-compromised environments rely on mitochondrial metabolism for energy metabolism and survival [19, 20] . Inhibiting [8, [19] [20] [21] . In this work, we report that doxycycline effectively targeted glioblastoma and sensitized glioblastoma cells to chemotherapy through disrupting mitochondrial functions and inducing oxidative stress. Doxycycline is an attractive candidate for glioblastoma treatment as it is already an FDA-approved drug with known pharmacokinetics and toxicity.
We used both an in vitro culturing system and an in vivo xenograft mouse model to demonstrate the efficacy of doxycycline in glioblastoma. The two human glioblastoma cell lines used, A172 and U87, differ in genetic profiling and cellular origin [13] . Doxycycline significantly induced apoptosis and inhibited proliferation of both A172 and U87 cells ( Figure 1A, 1B) , suggesting that doxycycline was active against glioblastoma regardless of molecular heterogeneity. The anti-proliferative and pro-apoptotic effects of doxycycline were further confirmed by the reduction in PANC and increase in cleaved caspase-3 levels ( Figure 1C) . Importantly, the combination of doxycycline with temozolomide was more effective in inhibiting proliferation and inducing apoptosis of glioblastoma cells than doxycycline or temozolomide alone ( Figure 5A , 5B), suggesting that doxycycline enhances the responsiveness of chemo-resistant glioblastoma cells. This was consistent with the report by Onoda et al. that the combination of doxycycline with cyclooxygenase-2 inhibitor resulted in greater efficacy in colorectal cancer cells compared to single drug alone. In addition, doxycycline's in vivo efficacy as single drug and as a combination therapy with temozolomide has been demonstrated in a glioblastoma xenograft mouse model ( Figure 5C ). The inhibitory effects of doxycycline have been demonstrated in cervical cancer and breast cancer [7, 9, 10] . Our data supports the previous work on the anti-cancer activities of doxycycline and adds glioblastoma to the growing list of doxycycline-targeted cancers.
We next demonstrated that the mechanism of action of doxycycline in glioblastoma was the disruption of mitochondrial functions and induction of oxidative stress. We showed that doxycycline induced mitochondrial dysfunctions via decreasing mitochondrial membrane potential and respiration (Figure 2A-2C ), leading to reduction in ATP generation in glioblastoma cells ( Figure 2D ). This finding was in agreement with previous work that showed doxycycline impaired mitochondrial respiration in cervical cancer cells and altered metabolism in various tumor cell lines and resulted in inhibition of growth and survival in tumor cells [9, 11] . to inhibit cancer cells or cancer stem cells via targeting mitochondrial functions [20, 22] . The critical role of mitochondrial metabolism has been shown in not only tumor cells but also quiescent tumor stem cells [8, [19] [20] [21] . Our work together with the previous work suggests that the inhibitory effects of some antibiotics on mitochondrial functions can be used to eradicate cancer cells, including cancer stem cells.
We further showed that doxycycline significantly increases the levels of mitochondrial superoxide and intracellular ROS in glioblastoma cells ( Figure 2E, 2F) . These results suggested that doxycycline caused oxidative stress. We further showed that doxycycline increased the levels of 8-OHdG, protein carbonylation, and lipid peroxidation (Figure 3 ), suggesting that oxidative stress induced by doxycycline caused oxidative damage in cellular DNA, protein, and lipids in glioblastoma cells. Although mitochondria has been identified as a target of doxycycline in various types of tumor cells [9, 11] , we are the first to demonstrate that oxidative stress and damage is the consequence of mitochondrial dysfunctions induced by doxycycline. In addition, antioxidant NAC significantly abolished the effects of doxycycline in inducing oxidative stress, inhibiting proliferation, and inducing apoptosis in glioblastoma cells (Figure 4) . These results further confirm that oxidative damage is the mechanism of the action of doxycycline in glioblastoma cells.
Mitochondrial functions and oxidative stress are also involved in various physiological functions of normal cells and biological process [23] . Mitochondrial dysfunction has been reported to induce psychiatric disorders [24] . More research on the understanding of the differential dependence in mitochondrial functions between tumors versus normal cells is needed to develop optimized therapeutic regimens. In addition, the direct molecular target(s) of doxycycline in glioblastoma are not clear although our work showed that mitochondrial dysfunction and oxidative damage were responsible for the action of doxycycline. Identification of doxycycline's binding partner(s) is important to understand the effectiveness of doxycycline in glioblastoma. 
Conclusions
Our work is the first to suggest the potential of doxycycline to be repurposed for glioblastoma treatment, given its efficacy as a single agent and as a combination agent with temozolomide in an in vitro cell culturing system and an in vivo xenograft mouse model. Our work also demonstrated the therapeutic value of inducing mitochondria dysfunction and oxidative stress in the treatment of glioblastoma.
Conflict of interest
All authors declare no conflict of interest. 
